Literature DB >> 10660743

[A case of unresectable gallbladder cancer responding to combination therapy with hyperthermia and local chemotherapy].

Y Hara1, T Kawasaki, E Yabata, T Gen, M Jibiki, A Kudoh, N Noguchi, T Kataoka, K Teramoto, T Iwai.   

Abstract

A 78-year-old woman was admitted to our hospital for the control of gallbladder cancer. A peritoneal metastasis, diagnosed as unresectable cancer, was detected during surgery in a previous hospital, and a biliary stent was introduced and gastrojejunostomy was performed. In our hospital she was treated weekly with local chemotherapy (PFL; cisplatin 2.5-5 mg/body ia, fluorouracil 300 mg/body ia, and calcium folinate 30 mg/body ia, via the common hepatic arterial port) at the time of hyperthermia. Hyperthermia was performed with a Thermox 500 (HEH-500 C) at the power of 500 watts for 45-60 minutes. To enhance the hyperthermia effect, mitomycin C 2-4 mg/body ia via the common hepatic arterial port and 500 ml of 7.5% glucose infusion were given. As a result of the combination therapy, the volume of the whole tumor was reduced to 60.9% on computed tomography, and diagnosed as PR. The serum level of CA19-9 decreased from 3,000 U/ml to 300 U/ml. The patient continued to receive the therapy for 1 year, and is now well. Therefore, we conclude that combination therapy with hyperthermia and local chemotherapy seems beneficial in managing unresectable advanced gallbladder cancer, especially for the elderly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10660743

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.

Authors:  Jae-Yong Cho; Ji-Sun Nam; Mi-Suk Park; Jeong-Sik Yu; Yong-Han Paik; Se-Joon Lee; Dong-Ki Lee; Dong-Sup Yoon
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

2.  A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.

Authors:  D C Doval; J S Sekhon; S K Gupta; J Fuloria; V K Shukla; S Gupta; B S Awasthy
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.